Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2022-05-03 00:00:00 ET · period of report 2022-04-29 · accession 0000899243-22-016316 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-05-03 | 2022-04-29 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $276.17 | -766 | 42.0K | -2% | -$211.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-04-29 | F | D | 766 | $276.17 | 42,016 | D | — | — |